Shots:

• Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31- 2021
• The portfolio to be divested includes OTC medicines and health products along with its lead product in the region- Alinamin. Blackstone plans to develop the business together with current TCHC management and continue to employ its employees
• The divestiture allows Takeda to refocus on its five key business areas and reduce debt after its $59 billion acquisition of Shire

­ Ref: Takeda | Image:Takeda